The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...
VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...
Stem cell therapy has come a long way since its early days. As an athlete who has undergone it twice, I know that the ...
Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...
New Treatments for HR-Positive Breast Cancer and Mantle Cell Lymphoma Offer Promising Outcomes and Expanded Options for ...
The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...
A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus ...
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback